Oxirane

Oxirane

SCHEMBL96722

C1CO1.OCC1CCC(CO)CC1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.39
ESR2 Q92731 6/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
APLNR P35414 1/20 0.35
CYP2D6 P10635 1/20 0.34
GBA1 P04062 2/20 0.31
TTR P02766 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4610 0.86
SCHEMBL297828 0.86 ESR2 (0.46) ESR1ESR2CYP3A4CYP2C9APLNR
SCHEMBL130642 0.86 ESR2 (0.46) ESR1ESR2CYP3A4CYP2C9APLNR
SCHEMBL2267415 0.86 ESR2 (0.46) ESR1ESR2CYP3A4CYP2C9APLNR
SCHEMBL1316560 0.86 ESR2 (0.46) ESR1ESR2CYP3A4CYP2C9APLNR
SCHEMBL27912 0.86 ESR2 (0.46) ESR1ESR2CYP3A4CYP2C9APLNR
SCHEMBL104405 0.84
Dioxane SCHEMBL5992701 0.83 ESR1 (0.34) ESR1ESR2CYP3A4CYP2C9CYP2D6
Phosphine SCHEMBL23581883 0.82 ESR1 (0.44) ESR1ESR2CYP3A4CYP2C9APLNR
SCHEMBL8744483 0.82 ESR1 (0.44) ESR1ESR2CYP3A4CYP2C9APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024141334-A1 THIOL MASTERBATCH COMPOSITIONS AND METHODS OF PREPARING ULTRAVIOLET-CURABLE COMPOSITIONS ARKEMA FRANCE (FR) 2024-07-04 WO disclosed
EP-4393990-A1 THIOL MASTERBATCH COMPOSITIONS AND METHODS OF PREPARING ULTRAVIOLET-CURABLE COMPOSITIONS ARKEMA FRANCE (FR) 2024-07-03 EP disclosed
CN-114127145-B (Meth) acrylate functionalized oligomers and methods of making and using such oligomers 阿科玛法国公司 2024-07-02 CN disclosed
US-20240199770-A1 CURABLE COMPOSITION COMPRISING A PHOTOINITIATOR ARKEMA FRANCE (FR) 2024-06-20 US disclosed
US-20240166621-A1 TYPE-II PHOTOINITIATORS ARKEMA FRANCE (FR) 2024-05-23 US disclosed
CN-118019774-A Branched acrylate functional oligomers 阿科玛法国公司 2024-05-10 CN disclosed
CN-118019645-A Photosensitive composition 阿科玛法国公司 2024-05-10 CN disclosed
US-20240141078-A1 AMINE CO-INITIATOR MIXTURE ARKEMA FRANCE (FR) 2024-05-02 US disclosed
EP-4341316-A1 POLYMERIZABLE FLAME RETARDANT ARKEMA FRANCE (FR) 2024-03-27 EP disclosed
EP-4301742-A1 TYPE-II PHOTOINITIATORS ARKEMA FRANCE (FR) 2024-01-10 EP disclosed
US-9303123-B2 Energy-ray-curable elastomer composition, material for gasket, gasket, and hard disk device BRIDGESTONE CORPORATION (JP) 2016-04-05 US disclosed
EP-2471873-B1 ENERGY RAY-CURABLE GASKET BRIDGESTONE CORP (JP) 2015-09-30 EP disclosed
US-20150080509-A1 PHOTOCURABLE MATERIAL FOR SEALING, SEALING METHOD, SEALING MATERIAL, AND HOUSING USING SAID SEALING MATERIAL NITTA GELATIN KK (JP) 2015-03-19 US disclosed
US-8921446-B2 Photocurable material for sealing, sealing method, sealing material, and housing using said sealing material NITTA GELATIN INC. (JP) 2014-12-30 US disclosed
US-20140370436-A1 LIQUID DEVELOPER Konica Minolta, Inc. (JP) 2014-12-18 US disclosed
US-20130303651-A1 PHOTOCURABLE MATERIAL FOR SEALING, SEALING METHOD, SEALING MATERIAL, AND HOUSING USING SAID SEALING MATERIAL BOSTIK SA (FR) 2013-11-14 US disclosed
EP-2471873-A1 ENERGY RAY-CURABLE ELASTOMER COMPOSITION Bridgestone Corporation (JP) 2012-07-04 EP disclosed
US-20120157564-A1 ENERGY RAY-CURABLE ELASTOMER COMPOSITION BRIDGESTONE CORPORATION (JP) 2012-06-21 US disclosed
EP-2426162-A1 ENERGY-RAY-CURABLE ELASTOMER COMPOSITION, MATERIAL FOR GASKET, GASKET, AND HARD DISK DEVICE Bridgestone Corporation (JP) 2012-03-07 EP disclosed
US-20120041096-A1 ENERGY-RAY-CURABLE ELASTOMER COMPOSITION, MATERIAL FOR GASKET, GASKET, AND HARD DISK DEVICE BRIDGESTONE CORPORATION (JP) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166621-A1 TYPE-II PHOTOINITIATORS NISCH, PPIH, DOHH ESR1 320/4885ESR2 120/4885CYP3A4 529/4885
US-20240141078-A1 AMINE CO-INITIATOR MIXTURE JMJD6, KDM2B, KDM1B ESR1 485/4885ESR2 849/4885CYP3A4 1013/4885
US-20240199770-A1 CURABLE COMPOSITION COMPRISING A PHOTOINITIATOR EED, CDH1, EPB41 ESR1 225/4885ESR2 1024/4885CYP3A4 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.